G. Steven Burrill

Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ.

Catalyst Bioscience, Inc. develops and markets catalytic biopharmaceutical products. Its technology consists of methods to identify proteases with tailor-made specificity or improved pharmacological properties. The company was founded by Charles Craik, Sandra Waugh Ruggles and Christopher Thanos in 2003 and is headquartered in South San Francisco, CA.

Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC.

Phytomedics, Inc. discovers, develops, and manufactures botanical therapeutics using proprietary platform technologies. The company was founded in December 1996 by Ilya Raskin and is headquartered in Jamesburg, NJ.

Third Wave Technologies, Inc. developed DNA and RNA detection technology. It provided molecular solutions for clinical, research, and agricultural customers. The company was founded in February 1993 and was headquartered in Madison, WI.

ProteoGenix is the first and only company solely committed to developing minimally invasive diagnostics that address unmet medical needs and improve pregnancy and neonatal management and outcomes. By applying innovative proteomic and molecular technologies, ProteoGenix has quickly become a leader in developing powerful diagnostic tools that have the potential to dramatically change the future of pregnancy and neonatal management. In 2002, four leading researchers in the area of perinatology and neonatology joined together to create ProteoGenix, a company dedicated to solving the mysteries of preterm birth and the significant medical, emotional and economic consequences that prematurity has on their society. Their passion for improving pregnancy management and the outcomes associated with preterm birth, along with their clinical expertise and scientific acumen, led ProteoGenix to achieve a truly significant recent scientific discovery identification of The Proteomic Map of Pregnancy. The physicians and scientists that became ProteoGenix were the first to identify and characterize a fundamental map of the key biologic fluids in pregnancy and show how this landscape changes in important pregnancy-related disorders. This groundbreaking work has received several significant scientific awards, including Best Clinical Study at the 2007 annual meeting of the Society for Maternal-Fetal Medicine, and has been the topic of numerous peer-reviewed publications. ProteoGenix has also developed the unique capability to utilize sophisticated nucleic acid-based molecular microbiology techniques such as quantitative Polymerase Chain Reaction (PCR) and Pyrosequencing, specifically optimized for use in key maternal, fetal, neonatal biological fluids to detect infectious and path physiological diseases associated with pregnancy.

Predictive Health Technologies, Inc. provides healthcare technology services. The company was founded by Ralph D. Snyderman and Jason M. Langheier in 2004 and is headquartered in Durham, NC.

Ikano Therapeutics Inc. (ITI) is a specialty pharmaceutical company focused on developing innovative therapeutics, with an emphasis on products treating disorders related to the central nervous system (CNS) for which there is proven, unsatisfied consumer need. They currently have two products in its clinical pipeline, with and others in formulation or preclinical development. Its goal is to become a leader in the field of specialty pharmaceuticals by applying its formulation expertise across a broad range of therapeutic areas to create new and differentiated products that improve safety, efficacy and convenience for patients, caregivers and health care professionals. ITI's fully integrated drug delivery platform combines proprietary formulation research, clinical and regulatory development, specialized delivery systems, clinical manufacturing and packaging. These capabilities and expertise enable them to develop its products efficiently and cost effectively. They intend to commercialize these products by marketing them themselves or partnering them with other companies. Its senior management team collectively has more than 100 years of experience in the pharmaceutical industry and extensive experience with development-stage companies. ITI supplements its own internal expertise with a variety of outside expert consultants, academic and industry and makes strategic use of outsourcing for development and commercial manufacturing.

BioImagene, Inc. provides innovative digital pathology solutions for the anatomic pathology laboratory. They are in the business of cancer diagnosis and its goal is to make detection, diagnosis, and therapy selection more accurate, efficient, reliable, and accessible. The firm's solutions allow pathologists to collaborate, learn, educate and provide more reliable and consistent diagnoses. Further, its solutions improve the efficiency of laboratory workflow. BioImagene provides digital pathology solutions. Its systems automate pathology workflows for acquisition, analysis, management, archival, reporting, and sharing of tissue images. The firm offers solutions for pathologists, researchers, and drug developers.

NewBridge Pharmaceuticals FZ LLC engages in the manufacture and distribution of pharmaceutical products, therapeutics and medical devices. The company was founded by G. Garrett Vygantas in 2007 and is headquartered in Dubai, United Arab Emirates.

Exploratorium engages as a museum of science, art and human perception activities . It creates tools and experiences that help people to become an active explorer. The firm includes film creenings workshops for life long learners as well as culture of learning through innovative environments, programs and tools that help people nurture their curiosity about the world around them. The company was founded in 1969 and is headquartered in San Francisco, CA.

AliveCor, Inc. develops mobile heart monitoring system. It offers kardia mobile that provides people with suspected or diagnosed heart conditions, and those at risk of heart conditions. The company was founded by David E. Albert, Bruce Satchwell, and Kim Barnett and is headquartered in San Francisco, CA.

Novadaq Technologies, Inc. was engaged in the development, manufacture, and market of real-time fluorescence imaging products. The company was founded by Rick Mangat on April 14, 2000 and was headquartered in Mississauga, Canada.

BioNJ, Inc. is based in Trenton, NJ. BioNJ, Inc. is a life sciences trade association with nearly 400 member companies. The company supports the discovery, development, and commercialization of therapies and cures that save and improve lives. BioNJ drives capital formation, fosters entrepreneurship, advocates for medical innovation, provides access to talent and education, and offers critical commercial resources. The company also serves as a clearinghouse for funding information and opportunities. The company was founded in 1994 by James J. Marino, Jayne C. Gershkowitz, Abraham Abuchowski. The CEO is Debbie Hart.

Buck Institute for Research on Aging operates independent research institute for connection between aging and chronic disease. The company is headquartered in Novato, CA.

Global Virus Network conducts research on essential and critical defense against viral diseases. The non-profit company is based in Baltimore, MD. The company was founded by William Walmsley Hall and Robert C. Gallo.

MIT Center for Biomedical Innovation improves global health by overcoming obstacles to the development and implementation of biomedical innovation. Its programs include Biomanufacturing Program, Consortium on Adventitious Agent Contamination in Biomanufacturing and New Drug Development Paradigms program. The company was founded by Frank Lennox Douglas in 2005 and is headquartered in Cambridge, MA.

The Life Sciences Foundation engaged in education and biotechnology information dissemination. It collected and organized historical information to educate future innovators, to engage the general public, and to provide lay audiences with an understanding of life sciences and biotechnology. The company was founded by G. Steven Burrill, Dennis Gillings, John Lechleiter, Henri Termeer, and Arnold Thackray in 2010 and was headquartered in San Francisco, CA.